Editorial Board

Jack E. Ansell, M.D.

Jack E. Ansell, M.D. is Professor of Medicine at Boston University School of Medicine and Vice Chairman for Clinical Affairs, Department of Medicine, at Boston University Medical Center.

Dr. Ansell received his medical degree from the University of Virginia School of Medicine. He completed his internship and residency in Internal Medicine at Tufts-New England Medical Center in Boston, and a fellowship in Hematology and Hemostasis at Boston University/Boston City Hospitals and the Boston VA Hospital. He is board certified in Internal Medicine and the subspecialty of Hematology.

Dr. Ansell's research has focused on the disciplines of Hemostasis and Thrombosis, especially in the areas of Thrombotic Disorders and Antithrombotic Therapy. He has had a continued interest and involvement in the application of new modes of delivering and monitoring anticoagulants, and particularly in the management of oral anticoagulant therapy. He has published extensively and lectured widely on these topics. He is the founder of the Anticoagulation Forum, a network of anticoagulation clinics throughout North America, and is a member of a number of professional organizations including the American College of Physicians (Fellow), American Society of Hematology, International Society of Thrombosis and Hemostasis and its Scientific Subcommittee on Anticoagulation Monitoring, American Heart Association, and American Medical Association. He Chairs the expert panel on Monitoring Oral Anticoagulant Therapy for the American College of Chest Physicians Consensus Guidelines for Antithrombotic Therapy and is an associate editor of the Journal of Thrombosis and Thrombolysis. He also serves as an editorial consultant for numerous journals including the New England Journal of Medicine, Annals of Internal Medicine, Blood, and Thrombosis & Hemostasis.

Dr. Ansell receives research support and is on speakers' bureaus for AstraZeneca, Aventis, Sanofi, and Roche. Additionally, he is an ad hoc medical advisor for AstraZeneca.

Editorial Board Members

• Henry I. Bussey, Pharm.D., FCCP, FAHA -- San Antonio, TX
• Marie B. Walker, BBA -- Fresno, CA & San Antonio, TX
• Mary Amato, Pharm.D., MPH -- Boston, MA
• Jack E. Ansell, M.D. -- Boston, MA
• William E. Dager, Pharm.D., FCSHP -- Sacramento, CA
• Susan C. Fagan, Pharm.D., BCPS, FCCP -- Augusta, GA
• Samuel Z. Goldhaber, M.D. -- Boston, MA
• James B. Groce III, Pharm.D., CACP -- Greensboro, NC
• Stuart T. Haines, Pharm.D., FCCP, FASHP, FAPhA -- W. Palm Beach, FL
• David W. Hawkins, Pharm.D. -- Sacramento, CA
• Elaine M. Hylek, MD, MPH -- Boston, MA
• Roger M. Lyons, MD, FACP -- San Antonio, TX
• Ruth Morrison, R.N., B.S.N., C.V.N. -- Boston, MA
• Edith A. Nutescu, Pharm.D. -- Chicago, IL
• Sarah A. Spinler, PharmD, FCCP, BCPS (AQ Cardiology) -- Philadelphia, PA
• Alex C. Spyropoulos, MD, FACP, FCCP -- Albuquerque, NM
• Victor F. Tapson, M.D. -- Durham, NC
• Alexander G.G. Turpie, MD, FRCP, FACP, FACC, FRCPC -- Hamilton, Ontario, Canada
• Robert T. Weibert, Pharm.D. -- San Diego, CA
• Ann K Wittkowsky, PharmD, CACP, FASHP, FCCP -- Seattle, WA